Birgitte Gangmark Villmo

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Pluvia Biotech is a spin-out from the University of Bergen (Norway) dedicated to developing "first in class" oral pharmacological chaperones for the treatment of Phenylketonuria (PKU). Through pioneering research and development, Pluvia Biotech aims to provide PKU patients with the opportunity to live life without the dietary constraints imposed by the condition. The company has significant momentum moving its lead compound towards clinical Proof of Concept.

Founded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis

Nisonic is developing an advanced ultrasound technology to measure the pressure in the brain (intracranial pressure) in a harmless and cost-effective way. Several indications can affect the intracranial pressure, including head trauma, stroke, meningitis and other central nervous system infections, brain tumours, etc. Today the only accurate measurement method is by invasive insertion of a sensor directly into the cranium, with the risks of bleeding, infections and damage to the brain tissue.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Pluvia Biotech is a spin-out from the University of Bergen (Norway) dedicated to developing "first in class" oral pharmacological chaperones for the treatment of Phenylketonuria (PKU). Through pioneering research and development, Pluvia Biotech aims to provide PKU patients with the opportunity to live life without the dietary constraints imposed by the condition. The company has significant momentum moving its lead compound towards clinical Proof of Concept.

APIM Therapeutics is a venture capital financed Norwegian biotech company focusing on the development of novel treatments in the fields of oncology and inflammation. Our lead drug, ATX-101, is a first-in-class peptide drug candidate targeting a novel therapeutic intervention point involved in cellular stress defense mechanisms. ATX-101 is currently being tested in a phase I study in patients with advanced solid tumors.

Founded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis

Investinor is an evergreen investment company funded by the Norwegian government. It invests in promising unlisted (private) companies aiming for international growth and expansion. Investinor manages NOK 4.2 billion (mEuro 525) and invests on the same terms and conditions as private investors, with a clear exit strategy for all investments. Investinor is one of the major venture investment companies in Norway, both in terms of manpower and capital under management. Our team has a superior overview of the market and attracts high quality dealflow.